SanBio Co Ltd (JP:4592)
:4592
Want to see JP:4592 full AI Analyst Report?
4592 Stock Chart & Stats
¥2230.00
¥19.00(2.53%)
At close: 4:00 PM EST
¥2230.00
¥19.00(2.53%)
Day’s Range― - ―
52-Week Range¥1,495.00 - ¥3,990.00
Previous CloseN/A
Volume765.40K
Average Volume (3M)2.08M
Market Cap
¥176.22B
Enterprise Value¥161.05B
Total Cash (Recent Filing)¥2.74B
Total Debt (Recent Filing)¥1.36B
Price to Earnings (P/E)―
Beta1.17
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding78,041,885
10 Day Avg. Volume2,869,570
30 Day Avg. Volume2,080,090
Financial Highlights & Ratios
PEG Ratio-1.38
Price to Book (P/B)9.94
Price to Sales (P/S)0.00
P/FCF Ratio-35.22
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
¥1,866.67Price Target Upside-16.29% Downside
Rating ConsensusModerate Sell
Number of Analyst Covering3
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Stronger Equity PositionA materially higher equity base and expanded assets improve solvency and extend runway versus prior years. For a clinical-stage biotech, higher equity reduces immediate refinancing pressure and gives management more flexibility to fund trials and partnerships over the next several months.
Manageable Leverage RecentlyDebt-to-equity at modest levels in recent years signals limited fixed‑charge burden versus peers, lowering bankruptcy risk as long as capital markets access remains. Stable, moderate leverage supports continued R&D investment while limiting interest drain on cash resources.
Improving Cash Burn From 2023 PeakReduction in cash outflows from the 2023 trough indicates management has taken steps to slow burn or prioritize spending. While still negative, a smaller annual cash deficit makes funding needs more predictable and reduces near-term dilution risk if the trend continues.
Bears Say
Zero Revenue BaseLack of any commercial revenue means the company remains fully development‑stage and dependent on financing or partnerships. Without product sales, sustainable profitability is distant and value hinges entirely on clinical success or licensing outcomes, raising binary risk.
Persistent Large LossesContinued multi‑billion yen net losses and deeply negative EBIT show the business has not reached breakeven. Ongoing losses erode equity over time absent offsets, increase future fundraising needs, and constrain the firm's ability to invest in parallel programs or scale operations.
Sustained Negative Cash FlowConsistent negative operating and free cash flow signals structural cash burn typical of clinical biotechs, implying repeated external financing or dilution. This reliance increases execution risk and could force unfavorable partner terms or R&D cuts if capital markets tighten.
SanBio Co News
4592 FAQ
What was SanBio Co Ltd’s price range in the past 12 months?
SanBio Co Ltd lowest stock price was ¥1495.00 and its highest was ¥3990.00 in the past 12 months.
What is SanBio Co Ltd’s market cap?
SanBio Co Ltd’s market cap is ¥176.22B.
When is SanBio Co Ltd’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were SanBio Co Ltd’s earnings last quarter?
Currently, no data Available
Is SanBio Co Ltd overvalued?
According to Wall Street analysts SanBio Co Ltd’s price is currently Overvalued.
Does SanBio Co Ltd pay dividends?
SanBio Co Ltd does not currently pay dividends.
What is SanBio Co Ltd’s EPS estimate?
SanBio Co Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does SanBio Co Ltd have?
SanBio Co Ltd has 78,041,885 shares outstanding.
What happened to SanBio Co Ltd’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of SanBio Co Ltd?
Currently, no hedge funds are holding shares in JP:4592
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
SanBio Co Ltd
SanBio Company Limited develops, produces, and sells regenerative cell medicines for the central nervous system. The company develops SB623 that has completed a phase 2 clinical trial to treat traumatic brain injury in the United States and Japan. Its research pipeline products also comprise SB623 for ischemic and hemorrhagic strokes, age-related macular degeneration, retinitis pigments, spinal cord injury, Parkinson's disease, Alzheimer's disease, and others; SB618 for peripheral nerve damage; SB308 for muscular dystrophy disease; MSC1 for cancer; and MSC2 for inflammatory disease and optic neuritis. The company was founded in 2001 and is headquartered in Tokyo, Japan.
4592 Company Deck
4592 Earnings Call
Q4 2026
0:00 / 0:00
4592 Stock 12 Month Forecast
Average Price Target
¥1,866.67
▼(-16.29% Downside)
Technical Analysis
Healios KK
―
StemRIM Inc.
―
ReproCELL Inc.
―
Japan Tissue Engineering Co., Ltd.
―
CellSeed Inc.
―
Options Prices
Currently, No data available
---